Asia Pacific Insulin Market Size, Share & Trends Analysis Report By Product, By Type, By Application, By Distribution, By Country, And Segment Forecasts 2024

Description

Asia Pacific Insulin Market Growth & Trends:

The Asia Pacific insulin market size is expected to reach USD 7.09 billion by 2030, expanding at a CAGR of 5.3% from 2024 to 2030, according to a new study by Grand View Research, Inc. Growing regional prevalence of diabetes, increasing market penetration rates of modern insulin products in emerging markets such as India and China is expected to drive market growth during the forecast period. Furthermore, patent expiration of key products such as Lantus is expected to trigger the manufacturing of biosimilars from local manufacturers such as Biocon.

Long-acting analog dominated the overall market in terms of revenue share in 2013, with revenue estimated at USD 2,051.9 million. High prices coupled with relatively higher efficacies exhibited by these products account for its large share. Rapid-acting analogs followed the long-acting segment in 2013 accounting for a revenue share of over 25.0% on account of their high market penetration rates in developed markets such as Australia and Japan.

Asia Pacific Insulin Market Report Highlights:

The long-acting segment dominated the regional market in 2023 with a share of 53.07%. This growth is primarily driven by the rising need for long-acting insulin due to applications in Type I diabetes and II diabetes across the region and the globe.
In 2023, the insulin analog segment held the largest revenue share of 88.6%. Insulin analog is created to mirror the pancreas' natural insulin release pattern, effectively regulating the body's blood sugar levels.
The market share for type I diabetes in the Asia Pacific region reached 79.03% in 2023. Type I diabetes application is further projected to experience substantial expansion as a result of the increasing incidence of type I diabetes in children and teenagers.
The retail & specialty pharmacies segment led the market and accounted for a revenue share of 89.9% in 2023. Looking toward the future, these pharmacies are projected to experience substantial growth.

Product Code: 978-1-68038-135-1

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Asia Pacific Insulin Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Asia Pacific Insulin Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Asia Pacific Insulin Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Asia Pacific Insulin Market: Product Movement Analysis, 2023 & 2030 (USD Million)
4.3. Rapid-Acting Insulin
- 4.3.1. Rapid-Acting Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Long-Acting Insulin
- 4.4.1. Long-Acting Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Combination Insulin
- 4.5.1. Combination Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Biosimilar
- 4.6.1. Biosimilar Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Others
- 4.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Asia Pacific Insulin Market: Type Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Asia Pacific Insulin Market: Type Movement Analysis, 2023 & 2030 (USD Million)
5.3. Human Insulin
- 5.3.1. Human Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Insulin Analog
- 5.4.1. Insulin Analog Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Asia Pacific Insulin Market: Application Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Asia Pacific Insulin Market: Application Movement Analysis, 2023 & 2030 (USD Million)
6.3. Type I Diabetes
- 6.3.1. Type I Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Type II Diabetes
- 6.4.1. Type II Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Asia Pacific Insulin Market: Distribution Channel Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Asia Pacific Insulin Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
7.3. Hospital Pharmacies
- 7.3.1. Hospitals Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Retail & Specialty Pharmacies
- 7.4.1. Retail & Specialty Pharmacies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Other Distribution Channels
- 7.5.1. Other Distribution Channels Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Asia Pacific Insulin Market: Country Estimates & Trend Analysis

8.1. Asia Pacific Insulin Market Share, By Country, 2023 & 2030 (USD Million)
8.2. Japan
- 8.2.1. Japan Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.3. China
- 8.3.1. China Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. India
- 8.4.1. India Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Australia
- 8.5.1. Australia Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. South Korea
- 8.6.1. South Korea Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Singapore
- 8.7.1. Singapore Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. Malaysia
- 8.8.1. Malaysia Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.9. Philippines
- 8.9.1. Philippines Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.10. Thailand
- 8.10.1. Thailand Insulin Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

9.1. Recent Developments & Impact Analysis by Key Market Participants
9.2. Company Categorization
9.3. Company Heat Map Analysis
9.4. Company Profiles
- 9.4.1. Novo Nordisk A/S
  - 9.4.1.1. Participant's Overview
  - 9.4.1.2. Financial Performance
  - 9.4.1.3. Product Benchmarking
  - 9.4.1.4. Recent Developments/Strategic Initiatives
- 9.4.2. Eli Lilly and Company
  - 9.4.2.1. Participant's Overview
  - 9.4.2.2. Financial Performance
  - 9.4.2.3. Product Benchmarking
  - 9.4.2.4. Recent Developments/Strategic Initiatives
- 9.4.3. Sanofi
  - 9.4.3.1. Participant's Overview
  - 9.4.3.2. Financial Performance
  - 9.4.3.3. Product Benchmarking
  - 9.4.3.4. Recent Developments/Strategic Initiatives
- 9.4.4. Biocon Ltd
  - 9.4.4.1. Participant's Overview
  - 9.4.4.2. Financial Performance
  - 9.4.4.3. Product Benchmarking
  - 9.4.4.4. Recent Developments/Strategic Initiatives
- 9.4.5. Wockhardt
  - 9.4.5.1. Participant's Overview
  - 9.4.5.2. Financial Performance
  - 9.4.5.3. Product Benchmarking
  - 9.4.5.4. Recent Developments/Strategic Initiatives
- 9.4.6. Boehringer Ingelheim International GmbH
  - 9.4.6.1. Participant's Overview
  - 9.4.6.2. Financial Performance
  - 9.4.6.3. Product Benchmarking
  - 9.4.6.4. Recent Developments/Strategic Initiatives
- 9.4.7. Julphar
  - 9.4.7.1. Participant's Overview
  - 9.4.7.2. Financial Performance
  - 9.4.7.3. Product Benchmarking
  - 9.4.7.4. Recent Developments/Strategic Initiatives
- 9.4.8. United Laboratories International Holdings Limited
  - 9.4.8.1. Participant's Overview
  - 9.4.8.2. Financial Performance
  - 9.4.8.3. Product Benchmarking
  - 9.4.8.4. Recent Developments/Strategic Initiatives
- 9.4.9. Tonghua Dongbao Pharmaceutical Co. Ltd.
  - 9.4.9.1. Participant's Overview
  - 9.4.9.2. Financial Performance
  - 9.4.9.3. Product Benchmarking
  - 9.4.9.4. Recent Developments/Strategic Initiatives
- 9.4.10. Gan & Lee Pharmaceuticals
  - 9.4.10.1. Participant's Overview
  - 9.4.10.2. Financial Performance
  - 9.4.10.3. Product Benchmarking
  - 9.4.10.4. Recent Developments/Strategic Initiatives

Asia Pacific Insulin Market Size, Share & Trends Analysis Report By Product, By Type, By Application, By Distribution, By Country, And Segment Forecasts 2024 - 2030